image
Healthcare - Medical - Devices - NASDAQ - US
$ 0.85
-1.38 %
$ 14.3 M
Market Cap
-1.57
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one IRIX stock under the worst case scenario is HIDDEN Compared to the current market price of 0.85 USD, IRIDEX Corporation is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one IRIX stock under the base case scenario is HIDDEN Compared to the current market price of 0.85 USD, IRIDEX Corporation is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one IRIX stock under the best case scenario is HIDDEN Compared to the current market price of 0.85 USD, IRIDEX Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart IRIX

image
$2.0$2.0$1.8$1.8$1.6$1.6$1.4$1.4$1.2$1.2$1.0$1.0$0.8$0.8$0.6$0.615 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
48.7 M REVENUE
-6.17%
-8.3 M OPERATING INCOME
17.04%
-8.91 M NET INCOME
6.90%
-7.28 M OPERATING CASH FLOW
-8.01%
-13 K INVESTING CASH FLOW
88.07%
2.6 M FINANCING CASH FLOW
52200.00%
12.7 M REVENUE
9.63%
-502 K OPERATING INCOME
73.16%
-834 K NET INCOME
56.85%
-1.24 M OPERATING CASH FLOW
59.71%
-9 K INVESTING CASH FLOW
-800.00%
-218 K FINANCING CASH FLOW
-7.72%
Balance Sheet IRIDEX Corporation
image
Current Assets 23.6 M
Cash & Short-Term Investments 2.39 M
Receivables 5.95 M
Other Current Assets 15.2 M
Non-Current Assets 5.57 M
Long-Term Investments 0
PP&E 1.91 M
Other Non-Current Assets 3.67 M
8.19 %20.43 %52.25 %6.55 %12.58 %Total Assets$29.1m
Current Liabilities 16.6 M
Accounts Payable 6.98 M
Short-Term Debt 1.09 M
Other Current Liabilities 8.48 M
Non-Current Liabilities 10.5 M
Long-Term Debt 811 K
Other Non-Current Liabilities 9.67 M
25.83 %4.05 %31.36 %3.00 %35.76 %Total Liabilities$27.0m
EFFICIENCY
Earnings Waterfall IRIDEX Corporation
image
Revenue 48.7 M
Cost Of Revenue 29.2 M
Gross Profit 19.5 M
Operating Expenses 27.8 M
Operating Income -8.3 M
Other Expenses 608 K
Net Income -8.91 M
50m50m40m40m30m30m20m20m10m10m00(10m)(10m)49m(29m)20m(28m)(8m)(608k)(9m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
40.07% GROSS MARGIN
40.07%
-17.06% OPERATING MARGIN
-17.06%
-18.31% NET MARGIN
-18.31%
-424.89% ROE
-424.89%
-30.58% ROA
-30.58%
-61.20% ROIC
-61.20%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis IRIDEX Corporation
image
10m10m8m8m6m6m4m4m2m2m00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)(12m)(12m)201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -8.91 M
Depreciation & Amortization 1.42 M
Capital Expenditures 0
Stock-Based Compensation 1.24 M
Change in Working Capital -1.37 M
Others -3.39 M
Free Cash Flow -7.28 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets IRIDEX Corporation
image
IRIX has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 13
6. Ownership
Insider Ownership IRIDEX Corporation
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
IRIDEX Corporation (IRIX) Q4 2024 Earnings Call Transcript IRIDEX Corporation (NASDAQ:IRIX ) Q4 2024 Earnings Conference Call March 27, 2025 5:00 PM ET Company Participants Trip Taylor - Investor Relations Department Patrick Mercer - Chief Executive Officer Romeo Dizon - Chief Financial Officer Conference Call Participants Operator Hello. And welcome to the Fourth Quarter 2024 IRIDEX Earnings Conference Call. seekingalpha.com - 3 weeks ago
Iridex Reports Fourth Quarter and Full Year 2024 Financial Results MOUNTAIN VIEW, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the fourth quarter and full year ended December 28, 2024. globenewswire.com - 3 weeks ago
Iridex Announces Strategic Investment in the Company MOUNTAIN VIEW, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems and delivery devices for the treatment of glaucoma and retinal diseases, today announced the closing of a strategic investment in the company resulting in $10 million of gross proceeds along with an option by the investor to fund up to $10 million of additional proceeds for future growth initiatives (the “Transaction”). The sole counterparty to the Transaction is Novel Inspiration International Co., Ltd. (“Novel”), an investment company founded in 2020, which had the assistance of William Moore, formerly both a board member and Chief Executive Officer of the company. globenewswire.com - 1 month ago
Iridex Comments on Recent Stock Price Volatility MOUNTAIN VIEW, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems and delivery devices for the treatment of glaucoma and retinal diseases, today commented on its recent stock price volatility. globenewswire.com - 1 month ago
Iridex to Report Fourth Quarter and Full Year 2024 Financial Results on March 27, 2025 MOUNTAIN VIEW, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems and delivery devices for the treatment of glaucoma and retinal diseases, today announced the Company plans to release financial results for the fourth quarter and full year 2024 and provide a business update after the close of trading on Thursday, March 27, 2025. globenewswire.com - 1 month ago
Iridex Announces Milestone Five-Year Study Confirms the Long-Term Effectiveness and Safety of MicroPulse Transscleral Cyclophotocoagulation for Glaucoma Management MOUNTAIN VIEW, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems and delivery devices for the treatment of glaucoma and retinal diseases, today announced the publication of a landmark peer-reviewed study in Ophthalmology Therapy. This study highlights the sustained safety and efficacy of MicroPulse Transscleral Laser Therapy (TLT) (also referred to as Transscleral Cyclophotocoagulation) in managing both primary and secondary glaucoma over five years. Conducted by Dr. Ronald de Crom and colleagues at the University Eye Clinic Maastricht, Netherlands, this research is the first to evaluate outcomes of MicroPulse TLT over such an extended period. globenewswire.com - 4 months ago
Iridex Comments on Changing Glaucoma Reimbursement Landscape MOUNTAIN VIEW, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today confirms that Local Coverage Determination (LCD) L37531, relating to Micro-Invasive Glaucoma Surgery (MIGS), was adopted as scheduled and will be effective for services performed on or after November 17, 2024. The Company has previously reported that it believes the reimbursement limitations created by the new LCD has potential to significantly increase physician interest in and use of Iridex's advanced laser-based treatments for glaucoma. globenewswire.com - 5 months ago
IRIDEX Corporation (IRIX) Q3 2024 Earnings Call Transcript IRIDEX Corporation (NASDAQ:IRIX ) Q3 2024 Earnings Call Transcript November 12, 2024 5:00 PM ET Company Participants Scott Shuda - Executive Chairman Patrick Mercer - CEO Fuad Ahmad - Interim CFO Operator Thank you all for participating in today's call. Joining me from the company are Scott Shuda, Executive Chairman; Patrick Mercer, Chief Executive Officer; and Fuad Ahmad, Interim Chief Financial Officer. seekingalpha.com - 5 months ago
Iridex to Report Third Quarter 2024 Financial Results on November 12, 2024 MOUNTAIN VIEW, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the third quarter 2024 and provide a business update after the close of trading on Tuesday, November 12, 2024. globenewswire.com - 5 months ago
Iridex Appoints Patrick Mercer as Chief Executive Officer MOUNTAIN VIEW, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the appointment of Patrick Mercer as the Company's Chief Executive Officer and President effective October 1, 2024. Previously Mr. Mercer served as the Company's Chief Operating Officer and President. David Bruce, the Company's prior Chief Executive Officer, is transitioning from the Company. Coincident to Mr. Mercer's appointment, Scott Shuda was appointed Executive Chairman of the Company's board of directors. Mr. Shuda had previously served as Chairman. globenewswire.com - 6 months ago
Iridex Frustrates, But Expect A Transaction By Year-End IRIDEX has faced delays in selling its assets as part of a strategic review initiated a year ago, causing frustration among shareholders. Despite setbacks, the company remains committed to selling all assets and has taken steps to ensure financial sustainability during the process. The CEO expects agreements for the sale of assets by the end of 2024, potentially doubling the current share price within the next 3-6 months. seekingalpha.com - 7 months ago
IRIDEX Corporation (IRIX) Q2 2024 Earnings Call Transcript IRIDEX Corporation (NASDAQ:IRIX ) Q2 2024 Earnings Conference Call August 8, 2024 5:00 PM ET Company Participants Philip Taylor – Investor Relations David Bruce – Chief Executive Officer Fuad Ahmad – Interim Chief Financial Officer Conference Call Participants Tom Stephan – Stifel Operator Good day, and thank you for standing by. At this time I would like to welcome everyone to IRIDEX Second Quarter 2024 Earnings Conference Call. seekingalpha.com - 8 months ago
8. Profile Summary

IRIDEX Corporation IRIX

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 14.3 M
Dividend Yield 0.00%
Description IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.
Contact 1212 Terra Bella Avenue, Mountain View, CA, 94043 https://www.iridex.com
IPO Date Feb. 16, 1996
Employees 93
Officers Mr. Romeo R. Dizon Chief Financial Officer Mr. Patrick Mercer Chief Executive Officer, President & Director Mr. Scott A. Shuda J.D. Executive Chairman Ms. Leigh Salvo Head of Investor Relations